Literature DB >> 20027656

Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis.

Joel R Pekow1, Jeremy T Hetzel, Jami A Rothe, Stephen B Hanauer, Jerrold R Turner, John Hart, Amy Noffsinger, Dezheng Huo, David T Rubin.   

Abstract

BACKGROUND: The management of low-grade (LGD) and indefinite dysplasia (IND) in patients with ulcerative colitis (UC) remains controversial, as outcomes after a diagnosis of LGD or IND in previous studies vary widely.
METHODS: All patients evaluated were from a single institution referral center who had a history of UC and a diagnosis of either LGD or IND between 1994 and 2008 as confirmed by 2 expert gastrointestinal (GI) pathologists. Data were collected by chart review of electronic and paper medical records. All patients who did not undergo a colectomy within 90 days of their dysplasia diagnosis were included in the final analysis. Hazard ratios for risk factors as well as incidence rates and Kaplan-Meier estimates were used to calculate the progression to high-grade dysplasia (HGD) or colorectal cancer (CRC).
RESULTS: Thirty-five patients were included in the analysis, of whom 2 patients with IND and 2 patients with LGD developed HGD or CRC over a mean duration of 49.8 months. In total, the incident rate for advanced neoplasia for all patients was 2.7 cases of HGD or CRC per 100 person-years at risk. For flat and polypoid LGD the incident rate of advanced neoplasia was 4.3 and 1.5 cases per 100 person-years at risk, respectively. Patients with primary sclerosing cholangitis (PSC) had an incident rate of 10.5 cases per 100 years of patient follow-up.
CONCLUSIONS: We report a low rate of progression to HGD or CRC in patients who underwent surveillance for LGD or IND; polypoid dysplasia showed less risk of progression than flat dysplasia.

Entities:  

Mesh:

Year:  2010        PMID: 20027656      PMCID: PMC3046461          DOI: 10.1002/ibd.21184

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  22 in total

1.  Colorectal cancer prevention in ulcerative colitis: a case-control study.

Authors:  J Eaden; K Abrams; A Ekbom; E Jackson; J Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

2.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

3.  Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

4.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.

Authors:  M Engelsgjerd; F A Farraye; R D Odze
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

6.  The fate of low grade dysplasia in ulcerative colitis.

Authors:  Thomas A Ullman; Edward V Loftus; Sanjay Kakar; Lawrence J Burgart; William J Sandborn; William J Tremaine
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

7.  Family history as a risk factor for colorectal cancer in inflammatory bowel disease.

Authors:  J Askling; P W Dickman; P Karlén; O Broström; A Lapidus; R Löfberg; A Ekbom
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

8.  Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.

Authors:  Thomas Ullman; Victoria Croog; Noam Harpaz; David Sachar; Steven Itzkowitz
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

9.  Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?

Authors:  David T Rubin; Jami A Rothe; Jeremy T Hetzel; Russell D Cohen; Stephen B Hanauer
Journal:  Gastrointest Endosc       Date:  2007-04-23       Impact factor: 9.427

10.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

View more
  24 in total

Review 1.  Endoscopic submucosal dissection in the colorectum: Feasibility in the Canadian setting.

Authors:  Marietta Iacucci; Gregory Eustace; Toshio Uraoka; Yutaka Saito; Miriam Fort Gasia; Jon Love; Naohisa Yahagi
Journal:  Can J Gastroenterol       Date:  2013-12       Impact factor: 3.522

Review 2.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

Review 3.  Ulcerative colitis-associated colorectal cancer.

Authors:  Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 4.  Novel diagnostic and therapeutic techniques for surveillance of dysplasia in patients with inflammatory bowel disease.

Authors:  Marietta Iacucci; T Uraoka; M Fort Gasia; N Yahagi
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

Review 5.  Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease.

Authors:  Samir A Shah; David T Rubin; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2014-09

Review 6.  An Update on Surveillance in Ulcerative Colitis.

Authors:  Jimmy K Limdi; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2018-03-07

Review 7.  Colon Cancer: Inflammation-Associated Cancer.

Authors:  Sherief Shawki; Jean Ashburn; Steven A Signs; Emina Huang
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

8.  Clinical significance of indefinite for dysplasia on pouch biopsy in patients with underlying inflammatory bowel disease.

Authors:  Zhao-Xiu Liu; Xiu-Li Liu; Deepa T Patil; Lei Lian; Ravi P Kiran; Feza H Remzi; Run-Zhou Ni; Bo Shen
Journal:  J Gastrointest Surg       Date:  2011-11-29       Impact factor: 3.452

Review 9.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 10.  Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis.

Authors:  Mathurin Fumery; Parambir S Dulai; Samir Gupta; Larry J Prokop; Sonia Ramamoorthy; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-01       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.